Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The remedy affords a non-surgical possibility for sufferers who will not be candidates for repeat procedures.The U.S. Meals and Drug Administration has permitted...
Rusfertide decreased phlebotomy want and improved high quality of life in sufferers with polycythemia vera, based on part 3 VERIFY trial outcomes.Remedy with...
